SAB Biotherapeutics Files 8-K
Ticker: SABSW · Form: 8-K · Filed: May 21, 2024 · CIK: 1833214
| Field | Detail |
|---|---|
| Company | Sab Biotherapeutics, Inc. (SABSW) |
| Form Type | 8-K |
| Filed Date | May 21, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-event, filing, financials
TL;DR
SAB Biotherapeutics filed an 8-K on 5/21/24, updating corporate info and financials.
AI Summary
SAB Biotherapeutics, Inc. filed an 8-K on May 21, 2024, reporting other events and financial statements. The company was formerly known as Big Cypress Acquisition Corp. and changed its name on November 20, 2020. SAB Biotherapeutics is incorporated in Delaware and its principal executive offices are located in Miami Beach, Florida.
Why It Matters
This filing provides an update on corporate events and financial reporting for SAB Biotherapeutics, Inc., which may be relevant for investors tracking the company's regulatory and financial status.
Risk Assessment
Risk Level: low — This filing is primarily administrative and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- SAB Biotherapeutics, Inc. (company) — Registrant
- Big Cypress Acquisition Corp. (company) — Former company name
- May 21, 2024 (date) — Date of report
- November 20, 2020 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing for SAB Biotherapeutics, Inc.?
The filing reports 'Other Events' and 'Financial Statements and Exhibits' as of May 21, 2024.
When did SAB Biotherapeutics, Inc. change its name from Big Cypress Acquisition Corp.?
The company changed its name on November 20, 2020.
In which state is SAB Biotherapeutics, Inc. incorporated?
SAB Biotherapeutics, Inc. is incorporated in Delaware.
What is the address of SAB Biotherapeutics, Inc.'s principal executive offices?
The principal executive offices are located at 777 W 41st St Suite 401, Miami Beach, Florida, 33140.
What is the SIC code for SAB Biotherapeutics, Inc.?
The Standard Industrial Classification code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 465 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-05-21 07:30:11
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share SABS The Nasdaq
Filing Documents
- sabs-20240521.htm (8-K) — 40KB
- sabs-ex99_1.htm (EX-99.1) — 17KB
- 0000950170-24-062656.txt ( ) — 208KB
- sabs-20240521.xsd (EX-101.SCH) — 46KB
- sabs-20240521_htm.xml (XML) — 6KB
01 Other Events
Item 8.01 Other Events. On May 21, 2024, SAB Biotherapeutics, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has provided clearance for the Company's investigational new drug application to proceed for the Company's type 1 diabetes therapy, SAB-142. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release of the Company, dated May 21, 2024 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SAB Biotherapeutics, Inc. Date: May 21, 2024 By: /s/ Michael G. King, Jr. Michael G. King, Jr. Chief Financial Officer